ArticleFrontiers in immunology2019
PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Postpartum breast cancer as a distinct oncologic entity: linking physiological tissue remodelling to tumor biology and clinical translation.Breast cancer research : BCR · 2026Review
- Reproductive state controls transcription in the murine liver, with implications for breast cancer liver metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer.Cell reports · 2025Article
- Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.NPJ breast cancer · 2025Article
- Immune Cell Contribution to Mammary Gland Development.Journal of mammary gland biology and neoplasia · 2024Review
- Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer.Journal of cancer research and clinical oncology · 2023Article
- Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis.Breast cancer research and treatment · 2023Article
- Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis.American journal of physiology. Cell physiology · 2022Review
- Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.Nature communications · 2021Article
- Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2021Review
- Article
- Macphatics and PoEMs in Postpartum Mammary Development and Tumor Progression.Journal of mammary gland biology and neoplasia · 2020Review
- Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?Cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Post-partum breast cancer patients, or breast cancer patients diagnosed within 10 years of last childbirth, are ~3-5 times more likely to develop metastasis in comparison to non-post-partum, or nulliparous, patients. Additionally, post-partum patients have increased tumor-associated lymphatic vessels and LN involvement, including when controlled for size of the primary tumor. In pre-clinical,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.